Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

727.45 -18.50 (-2.48%)
Streaming Delayed Price Updated: 2:24 PM EDT, Apr 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
83 84 Next >
7 A-Rated Aggressive Biotech Stocks to Bet On in 2024
We’re using the Portfolio Grader to find the best biotech stocks to buy in today’s market. Each of these stocks get top grades. 
Via InvestorPlace
Shed the Fat, Gain the Profits: 3 Weight-Loss Stocks to Own Until 2027
For investors looking for a way to play weight-loss stocks in this current backdrop, here are three top options to consider right now. 
Via InvestorPlace
Why Roche Holdings Stock Popped Today
Roche's new Alzheimer's test has a long road ahead of it, but it may help boost the pharmaceutical company's slow growth rate. 
Via The Motley Fool
Wall Street Favorites: 3 Healthcare Stocks With Strong Buy Ratings for April 2024
Investors wanting to broaden and deepen their portfolio should reach for these healthcare names, each of which is a favorite among analysts. 
Via InvestorPlace
Trillion-Dollar Trajectories: 3 Billion-Dollar Stocks With the Potential to Hit the Next Milestone
Looking for your next picks? These top-performing market leaders have the potential to be the next trillion-dollar companies. 
Via InvestorPlace
Eli Lilly and Co's Options: A Look at What the Big Money is Thinking
Via Benzinga
Understanding Eli Lilly and Co's Position In Pharmaceuticals Industry Compared To Competitors
Via Benzinga
Eli Lilly and Co Options Trading: A Deep Dive into Market Sentiment
Via Benzinga
3 Obesity Drug Stocks Set to Skyrocket as Demand Goes Wild
Discover top obesity drug stocks set to soar as demand surges. Eli Lilly, Novo Nordisk, & Dexcom lead with revolutionary treatments 
Via InvestorPlace
Amphastar Pharmaceuticals Interested In Potential Acquisitions In Endocrinology-Focused Companies
Amphastar Pharmaceuticals discusses the future of Baqsimi at the Needham Healthcare Conference, highlighting its potential amid a growing market for glucagon products. With promising sales projections... 
Via Benzinga
The Next "Magnificent Seven"?
Here is a look at the stocks that might comprise the next "Magnificent Seven." 
Via The Motley Fool
Jim Cramer Stands By Nvidia And Eli Lilly Despite Market Dips, Says 'Terrific Time To Take Some Profits'
Cramer observed that despite the losses, these stocks have a lot to offer. He noted that these stocks have surged so much that they've become susceptible to market volatility. 
Via Benzinga
MarketMasterAI’s Top 500 Stocks: April 2024
My MarketMasterAI system has ranked the top 500 stocks to buy in April and the winners look really different than in January. Here's why. 
Via InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
3 High-Growth Biotech Stocks Investors Shouldn’t Sleep On in April
These high-growth biotech stocks are certainly worth considering for investors looking for market-beating returns in the long-term. 
Via InvestorPlace
Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon.
These companies are close to launching new products that could supercharge revenue. 
Via The Motley Fool
Can Altimmune get its GLP-1 Drug to Market Before Cash Rush Out?
Altimmune has a GLP-1 candidate in Phase 2 trials, but the company continues to burn cash and may need a big pharma partner to get its drug to market 
Via MarketBeat
Exposures Product Safety
Bull Market and Beyond: 3 Stocks Just Waiting to Soar
These stocks, a bargain today, are players to hold on to for the long term. 
Via The Motley Fool
Will the Shockwave Medical Deal Be the Jolt JNJ Stock Needs?
Johnson & Johnson's proposed acquisition of Shockwave Medical may be the jolt that JNJ stock needs to break out of a year-long downtrend 
Via MarketBeat
ProfoundBio Discovers The Joys Of Having A Wealthy Owner
Key Takeaways: Cancer treatment maker ProfoundBio announced it will be purchased by Denmark’s Genmab for $1.8 billion The deal is the fourth acquisition of a China-related innovative drugmaker by a... 
Via Benzinga
2 Growth Stocks to Buy Hand Over Fist in April
These healthcare companies' target markets substantially overlap. 
Via The Motley Fool
This 1 Number May Ensure Eli Lilly's Dominance in the Weight Loss Drug Market
Lilly's stock has climbed in the triple digits over the past 12 months. 
Via The Motley Fool
Viking Therapeutics Is Great. Here's Why You Shouldn't Buy It.
Shares of the clinical-stage biotech have skyrocketed on recent good news. 
Via The Motley Fool
Could This New Development Soon Buoy Eli Lilly and Novo Nordisk Stock?
New findings could lead to more growth from their prized medicines. 
Via The Motley Fool
Eli Lilly's Wegovy Competitor Is Causing Supply Constraints: What It Means for the Stock
Things are going exactly as planned for the biotech giant. 
Via The Motley Fool
Traders Rethink Interest Rate Cuts, Labor Market Heats Up, Oil Prices Quietly Reach 6-Month High: This Week In The Markets
U.S. economy resilient, manufacturing and labor market strong. Fed officials temper rate cut expectations. Apple shifts focus to home robotics. 
Via Benzinga
Topics Economy
Exposures Economy Interest Rates
Wondering Where To Find An Over 7% Annual Return? Check Out These 10 Investment-Grade Corporate Bonds
Corporate bonds offer yield opportunities and diversification away from equity investments. Investment-grade bonds are safer but lower yield, while high-yield bonds offer higher returns but from... 
Via Benzinga
Topics Bonds
Exposures Debt Markets
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Spring 2024 Snapshot Of The S&P 500's Market Cap
The first quarter of 2024 has come and gone. Before it did, the S&P 500 clocked a new record high of 5,254.35. 
Via Talk Markets
Topics Stocks
Exposures US Equities
3 Growth Stocks with Even Greater Potential Than the Magnificent 7
Here are three Magnificent 7 contenders growth investors shouldn't be sleeping on right now, given their long-term potential. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9
...
83 84 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.